{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:52:56Z","timestamp":1791114776984,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T00:00:00Z","timestamp":1393286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify the clinical and laboratory predictors of clinical improvement in a cohort of myositis patients treated with rituximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data for 195 patients with myositis (75 with adult polymyositis [PM], 72 with adult dermatomyositis [DM], and 48 with juvenile DM) in the Rituximab in Myositis trial. Clinical improvement was defined as 20% improvement in at least 3 of the following 6 core set measures of disease activity: physician's and patient's\/parent's global assessment of disease activity, manual muscle testing, physical function, muscle enzymes, and extramuscular disease activity. We analyzed the association of the following baseline variables with improvement: myositis clinical subgroup, demographics, myositis damage, clinical and laboratory parameters, core set measures, rituximab treatment, and myositis autoantibodies (antisynthetase, anti\u2013Mi\u20102, anti\u2013signal recognition particle, anti\u2013transcription intermediary factor 1\u03b3 [TIF\u20101\u03b3], anti\u2010MJ, other autoantibodies, and no autoantibodies). All measures were univariately assessed for association with improvement using time\u2010to\u2010event analyses. A multivariable time\u2010dependent proportional hazards model was used to evaluate the association of individual predictive factors with improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the final multivariable model, the presence of an antisynthetase, primarily anti\u2013Jo\u20101 (hazard ratio [HR] 3.08,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01), anti\u2013Mi\u20102 (HR 2.5,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01), or other autoantibody (HR 1.4,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.14) predicted a shorter time to improvement compared to the absence of autoantibodies. A lower physician's global assessment of damage (HR 2.32,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02) and juvenile DM (versus adult myositis) (HR 2.45,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.01) also predicted improvement. Unlike autoantibody status, the predictive effect of physician's global assessment of damage and juvenile DM diminished by week 20. Rituximab treatment did not affect these associations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that the presence of antisynthetase and anti\u2013Mi\u20102 autoantibodies, juvenile DM subset, and lower disease damage strongly predict clinical improvement in patients with refractory myositis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.38270","type":"journal-article","created":{"date-parts":[[2013,11,18]],"date-time":"2013-11-18T21:05:45Z","timestamp":1384808745000},"page":"740-749","source":"Crossref","is-referenced-by-count":259,"title":["Predictors of Clinical Improvement in Rituximab\u2010Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis"],"prefix":"10.1002","volume":"66","author":[{"given":"Rohit","family":"Aggarwal","sequence":"first","affiliation":[{"name":"University of Pittsburgh Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Bandos","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Reed","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana P.","family":"Ascherman","sequence":"additional","affiliation":[{"name":"University of Miami Miami Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Feldman","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children and University of Toronto Toronto, Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Miller","sequence":"additional","affiliation":[{"name":"National Institute of Environmental Health Sciences, NIH Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Rider","sequence":"additional","affiliation":[{"name":"National Institute of Environmental Health Sciences, NIH Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O.","family":"Harris\u2010Love","sequence":"additional","affiliation":[{"name":"Washington DC VA Medical Center Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Levesque","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the RIM Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-003-0052-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker518"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker408"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199111000-00002"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90148-I"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2011.608376"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20015"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20203"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20349"},{"key":"e_1_2_8_13_1","first-page":"603","article-title":"Defining clinical improvement in adult and juvenile myositis","volume":"30","author":"Rider LG","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23963"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01501.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00357-7"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.11.1262"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20035"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1164-z"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000109755.65914.5e"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916930600622603"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(02)00032-7"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22477"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045690"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780260505"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114461"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22865"},{"key":"e_1_2_8_30_1","first-page":"S325","article-title":"Effect of B cell depletion therapy with rituximab on myositis associated antibody levels in idiopathic inflammatory myopathy","volume":"64","author":"Aggarwal R","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.33.23155"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5411.147"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020186"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040717"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.52"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11484"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201800"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.61.3.316"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2009.24.4.715"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31827f264d"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199905000-00001"},{"key":"e_1_2_8_42_1","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis","volume":"28","author":"Marie I","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24904"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38270","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:43:37Z","timestamp":1759952617000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,25]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/art.38270"],"URL":"https:\/\/doi.org\/10.1002\/art.38270","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718180512.793487254","asserted-by":"object"}]},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,25]]}}}